Seroprevalence of SARS-CoV-2 antibodies and proportion of IgM-seropositive results in participants aged 5–17 years by region, area of residence and sex
| Number of positive COVID-19 tests† | Seroprevalence % (95% CI) | Number of IgM-positive COVID-19 tests | IgM-seropositive % COVID-19 tests (95% CI) | |
| National | 850 | 25.3 (20.5 to 30.8) | 89 | 3.3 (1.8 to 6.3) |
| Region* | Region** | |||
| Central | 79 | 21.0 (14.5 to 29.3)* | 10 | 2.8 (1.2 to 6.3) |
| Central highlands | 42 | 14.6 (8.6 to 23.8) | 3 | 1.6 (0.4 to 6.6) |
| East | 172 | 32.4 (26.8 to 38.6) | 10 | 1.4 (0.7 to 3.1) |
| Kabul | 177 | 46.4 (40.8 to 52.1) | 14 | 3.5 (1.6 to 7.3) |
| North | 96 | 23.0 (16.8 to 30.8) | 6 | 1.2 (0.4 to 3.7) |
| North-east | 108 | 20.9 (15.1 to 28.2) | 18 | 2.8 (1.0 to 7.6) |
| South | 55 | 24.4 (14.5 to 38.0) | 7 | 4.7 (1.6 to 13.1) |
| South-east | 42 | 17.6 (10.6 to 27.6) | 9 | 2.4 (0.8 to 6.8) |
| West | 79 | 24.5 (18.4 to 31.8) | 12 | 3.2 (1.7 to 6.0) |
| Area of residence | ||||
| Rural | 528 | 23.4 (17.5 to 30.6) | 60 | 3.7 (1.7 to 7.9) |
| Urban | 322 | 30.8 (24.8 to 37.5) | 29 | 2.3 (1.2 to 4.2) |
| Sex | ||||
| Male | 446 | 24.2 (18.5 to 31) | 47 | 2.4 (1.4 to 4.0) |
| Female | 401 | 27.8 (21.3 to 33) | 42 | 4.1 (1.8 to 9.2) |
| Age (years)** | Age** | |||
| 5–9 | 175 | (13.4 to 26.2) | 20 | 3.3 (1.1 to 9.5) |
| 10–14 | 365 | (20.8 to 33.8) | 40 | 3.7 (1.7 to 7.9) |
| 15–17 | 310 | (23.5 to 35.6) | 29 | 2.8 (1.5 to 5.2) |
*p<0.05, **p<0.01, ***p<0.001.
†The total number of positive COVID-19 tests includes all positive results: both current and past infections that is, IgG-positive, IgM-positive or both.